A Trial to Compare the Efficacy of Two Formulations of Avotermin Against Placebo

A Double-blind, Placebo Controlled, Randomised Trial to Compare the Efficacy of 250ng and 500ng RN1006 (a New Formulation of Avotermin) and 250ng and 500ng Juvista (Standard Avotermin Formulation), in the Improvement of Scar Appearance in Healthy Volunteer Subjects

RN1006 has been developed as a stabilized formulation of avotermin which, when dosed once in pre-clinical studies in animals, has shown comparable scar improvement efficacy to the standard twice-dosed Juvista formulation. The aim of this trial is to investigate the efficacy of RN1006 compared to Juvista in a human volunteer model

Inclusion Criteria:

• Males and females aged 18-85 years who have given written informed consent
• Subjects with a body mass index within range 18-35 kg/m2
• Subjects with clinically acceptable results for the laboratory tests specified in the trial protocol
• Female subjects using a highly effective method (S) of contraception

Exclusion Criteria:

• Subjects who have a history of keloid scarring, surgery within one year of the first dosing area
• Subjects who have current scars, tattoos, birthmarks, mole within 3 cm of the area to be excised
• Subjects with any clinically significant medical condition or history of any condition which may impair wound healing